Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua J Meeks

Showing results (191-200 of 208) with videos related to

Pageof 21
Sort By:
Oncogene|January 26, 2018
A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancerDamiano Fantini, Alexander P Glaser, Kalen J Rimar, et al.
JCO Precision Oncology|December 3, 2024
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic ReviewEmanuele Crupi, Tiago Costa de Padua, Laura Marandino, et al.
Nature Medicine|June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
European Urology|October 6, 2023
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial CarcinomaHeather L Huelster, Billie Gould, Elizabeth A Schiftan, et al.
Nature Medicine|July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
The Journal of Urology|October 9, 2025
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: ErratumJoshua J Meeks, Michiel S van der Heijden, Thomas Powles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
European Urology|February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Roger Li, Patrick J Hensley, et al.
Urologic Oncology|January 16, 2025
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancerSiamak Daneshmand, Ashish M Kamat, Neal D Shore, et al.
Pageof 21

Showing results (191-200 of 208) with videos related to

Sort By:
Pageof 21
Oncogene|January 26, 2018
A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancerDamiano Fantini, Alexander P Glaser, Kalen J Rimar, et al.
JCO Precision Oncology|December 3, 2024
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic ReviewEmanuele Crupi, Tiago Costa de Padua, Laura Marandino, et al.
Nature Medicine|June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
European Urology|October 6, 2023
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial CarcinomaHeather L Huelster, Billie Gould, Elizabeth A Schiftan, et al.
Nature Medicine|July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
The Journal of Urology|October 9, 2025
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: ErratumJoshua J Meeks, Michiel S van der Heijden, Thomas Powles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2019
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive TrialsMax Kates, Andres Matoso, Woonyoung Choi, et al.
European Urology|February 22, 2026
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer GroupShilpa Gupta, Roger Li, Patrick J Hensley, et al.
Urologic Oncology|January 16, 2025
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancerSiamak Daneshmand, Ashish M Kamat, Neal D Shore, et al.
Pageof 21